Table 3.
Patient characteristics
| Total | |
|---|---|
| (N = 17) | |
| Age, years | |
| Mean (SD) | 68.8 (8.5) |
| Median | 68 |
| Min-max | 54–84 |
| Sex | |
| Male | 15 (88.2%) |
| Female | 2 (11.8%) |
| Race | |
| White | 13 (76.4%) |
| Black or African American | 2 (11.8%) |
| Asian | 0 |
| Native Hawaiian or other Pacific Islander | 0 |
| American Indian or Alaskan native | 0 |
| Other | 1 (5.9%) |
| Not reported | 1 (5.9%) |
| Ethnicity | |
| Hispanic or Latino | 2 (11.8%) |
| Not Hispanic or Latino | 13 (76.4%) |
| Not reported | 2 (11.8%) |
| Living situation | |
| Living alone | 6 (35.3%) |
| Living with partner or spouse, family, or friends | 9 (52.9%) |
| Other | 1 (5.9%) |
| Not reported | 1 (5.9%) |
| Employment status | |
| Employed full time | 1 (5.9%) |
| Employed part time | 0 |
| Unemployed | 1 (5.9%) |
| Retired | 10 (58.8%) |
| Disabled | 2 (11.8%) |
| Other | 2 (11.8%) |
| Not reported | 1 (5.9%) |
| Education levela | |
| Secondary/high school | 2 (11.8%) |
| Some college | 7 (41.2%) |
| College degree | 4 (23.5%) |
| Postgraduate degree | 2 (11.8%) |
| Other or Missing | 2 (11.8%) |
| General health (past week) | |
| Very good | 3 (17.7%) |
| Good | 6 (35.3%) |
| Fair | 5 (29.4%) |
| Poor | 2 (11.8%) |
| Very poor | 0 |
| Not reported | 1 (5.9) |
| Child-Pugh class | |
| A—with no locoregional treatment | 3 (17.7%) |
| A—with locoregional treatment but before sorafenib treatment | 4 (23.5%) |
| A—after sorafenib treatment | 3 (17.7%) |
| B—with any treatment experience | 7 (41.2%) |
| ECOG performance status | |
| 0 | 8 (47.1%) |
| 1 | 9 (52.9%) |
| Comorbiditiesa | |
| Asthma | 2 (11.8%) |
| Anxiety/depression | 5 (29.4%) |
| Arthritis | 3 (17.7%) |
| COPD (emphysema, chronic bronchitis) | 3 (17.7%) |
| Diabetes | 4 (23.5%) |
| Hypertension (high blood pressure) | 10 (58.8%) |
| Chest pain/abdominal pain | 1 (5.9%) |
| No other health conditions | 2 (11.8%) |
| HCC treatments receiveda | |
| Chemotherapy | 2 (11.8%) |
| Transarterial chemoembolization | 5 (29.4%) |
| External radiation | 1 (5.9%) |
| Ablation | 8 (47.1%) |
| Liver resection | 4 (23.5%) |
| Y90 radioembolization | 6 (35.3%) |
| Sorafenib | 5 (29.4%) |
| Current medicationsa | |
| Antibiotics | 2 (11.8%) |
| Nutritional support | 2 (11.8%) |
| Pain medications/corticosteroids/anti-inflammatory agents | 5 (29.4%) |
| Drugs for gastrointestinal-related disorders | 6 (35.3%) |
| Drugs for anemia | 1 (5.9%) |
| None | 2 (11.8%) |
COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma
aNot mutually exclusive